Abstract:Importance: Current approaches to classify the hepatotoxic potential of medications are based on cumulative case reports of acute liver injury (ALI), which do not consider the size of the exposed population. There is little evidence from real-world data (data relating to patient health status and/or the delivery of health care routinely collected from sources outside of a research setting) on incidence rates of severe ALI after initiation of medications, accounting for duration of exposure. Objective: To identify the most potentially hepatotoxic medications based on real-world incidence rates of severe ALI and to examine how these rates compare with categorization based on case reports. Design, setting, and participants: This series of cohort studies obtained data from the US Department of Veterans Affairs on persons without preexisting liver or biliary disease who initiated a suspected hepatotoxic medication in the outpatient setting between October 1, 2000, and September 30, 2021. Data were analyzed from June 2020 to November 2023. Exposures: Outpatient initiation of any one of 194 medications with 4 or more published reports of hepatotoxicity. Main outcomes and measures: Hospitalization for severe ALI, defined by either inpatient: (1) alanine aminotransferase level greater than 120 U/L plus total bilirubin level greater than 2.0 mg/dL or (2) international normalized ratio of 1.5 or higher plus total bilirubin level greater than 2.0 mg/dL recorded within the first 2 days of admission. Acute or chronic liver or biliary disease diagnosis recorded during follow-up or as a discharge diagnosis of a hospitalization for severe ALI resulted in censoring. This study calculated age- and sex-adjusted incidence rates of severe ALI and compared observed rates with hepatotoxicity categories based on cumulative published case reports. Results: The study included 7 899 888 patients across 194 medication cohorts (mean [SD] age, 64.4 [16.4] years, 7 305 558 males [92.5%], 4 354 136 individuals [55.1%] had polypharmacy). Incidence rates of severe ALI ranged from 0 events per 10 000 person-years (candesartan, minocycline) to 86.4 events per 10 000 person-years (stavudine). Seven medications (stavudine, erlotinib, lenalidomide or thalidomide, chlorpromazine, metronidazole, prochlorperazine, and isoniazid) exhibited rates of 10.0 or more events per 10 000 person-years, and 10 (moxifloxacin, azathioprine, levofloxacin, clarithromycin, ketoconazole, fluconazole, captopril, amoxicillin-clavulanate, sulfamethoxazole-trimethoprim, and ciprofloxacin) had rates between 5.0 and 9.9 events per 10 000 person-years. Of these 17 medications with the highest observed rates of severe ALI, 11 (64%) were not included in the highest hepatotoxicity category when based on case reports. Conclusions and relevance: In this study, incidence rates of severe ALI using real-world data identified the most potentially hepatotoxic medications and can serve as a tool to investigate hepatotoxicity safety signals obtained from case reports. Case report counts did not accurately reflect the observed rates of severe ALI after medication initiation.

Assessment of the Frequency, Phenotypes, and Outcomes of Acute Liver Injury Associated with Amoxicillin/Clavulanate in 1.4 Million Patients in the Veterans Health Administration

Causal Evaluation of Post-Marketing Drugs for Drug-induced Liver Injury from Electronic Health Records*

Analysis and Prevention of Liver Injury Caused by Azithromycin:a Retrospective Study of 27 Cases

Incidence of amoxycillin-clavulanic acid associated hepatotoxicity in an Australian children’s hospital

Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data

Delayed Presentation of Drug-Induced Hepatic Injury

S4431 A Severe Case of Drug-Induced Liver Injury After Ingestion of Amoxicillin-Clavulanic Acid

Severe Case of Cholestatic Hepatitis From Amoxicillin/Clavulanic Acid

Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury

Identification of reduced ERAP2 expression and a novel HLA allele as components of a risk score for susceptibility to liver injury due to amoxicillin-clavulanate

Amoxicillin-induced Hepatotoxicity: Review of Medical Literatlires

Spotlight on Gut Microbiota, Fecal Metabolome and Bile Acid Profile in Patients

Risk factors for acute liver failure among inpatients with anti-tuberculosis drug-induced liver injury.

Hepatotoxicity of Antibiotics and Antifungals and Their Safe Use in Hepatic Impairment

Drug-Induced Acute-on-Chronic Liver Failure in Asian Patients

Study on the Automatic Monitoring System for ADR by Elevated Liver Enzymes Based on HIS

Underreporting Supplements: A Case of Drug-induced Liver Injury Due to a Testosterone Booster

Association of Acetaminophen (Paracetamol) Use with Severity and Outcomes in Patients with Viral Hepatitis-Associated Acute Liver Failure

Liver Injury in Children: Signal Analysis of Suspected Drugs Based on the Food and Drug Administration Adverse Event Reporting System

Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase

Amoxicillin‐induced crystal nephropathy: A nationwide French pharmacovigilance databases study